Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-HPV Oral Vaccine
- Development stage
- Preclinical
- Lead developer
- CHAIN Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Anti-HPV Oral Vaccine is an investigational oral vaccine program from CHAIN Biotech designed to deliver Human Papilloma Virus antigens using the company's CADD platform based on engineered non-pathogenic Clostridium butyricum spores. The candidate is described as an oral live bacterial spore vaccine and live bacterial vector intended for HPV infection, with the proposed mechanism of inducing mucosal and systemic immune responses against HPV antigens after lower gastrointestinal delivery. Publicly available pipeline information identifies the developer and platform, but does not disclose a specific code name, antigen composition, HPV genotype coverage, clinical phase, or detailed clinical data.
- Other names
- anti-HPV oral vaccineAnti-Human Papilloma Virus oral vaccineCADD oral HPV vaccine
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on Anti-HPV Oral Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-HPV Oral Vaccine.